OptiNose Inc (OPTN)
1.035
+0.02
(+1.47%)
USD |
NASDAQ |
May 08, 16:00
1.035
0.00 (0.00%)
After-Hours: 20:00
OptiNose Enterprise Value: 171.84M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 171.84M |
| May 06, 2024 | 185.41M |
| May 03, 2024 | 170.71M |
| May 02, 2024 | 155.75M |
| May 01, 2024 | 159.20M |
| April 30, 2024 | 149.35M |
| April 29, 2024 | 153.67M |
| April 26, 2024 | 153.80M |
| April 25, 2024 | 158.84M |
| April 24, 2024 | 161.14M |
| April 23, 2024 | 165.93M |
| April 22, 2024 | 172.97M |
| April 19, 2024 | 157.62M |
| April 18, 2024 | 161.41M |
| April 17, 2024 | 171.84M |
| April 16, 2024 | 179.76M |
| April 15, 2024 | 191.06M |
| April 12, 2024 | 194.45M |
| April 11, 2024 | 196.71M |
| April 10, 2024 | 197.84M |
| April 09, 2024 | 195.58M |
| April 08, 2024 | 206.37M |
| April 05, 2024 | 205.24M |
| April 04, 2024 | 210.88M |
| April 03, 2024 | 212.00M |
| Date | Value |
|---|---|
| April 02, 2024 | 215.38M |
| April 01, 2024 | 218.76M |
| March 28, 2024 | 221.01M |
| March 27, 2024 | 223.27M |
| March 26, 2024 | 223.27M |
| March 25, 2024 | 225.52M |
| March 22, 2024 | 240.17M |
| March 21, 2024 | 243.54M |
| March 20, 2024 | 249.74M |
| March 19, 2024 | 250.30M |
| March 18, 2024 | 274.52M |
| March 15, 2024 | 268.33M |
| March 14, 2024 | 270.58M |
| March 13, 2024 | 273.96M |
| March 12, 2024 | 270.02M |
| March 11, 2024 | 266.08M |
| March 08, 2024 | 245.80M |
| March 07, 2024 | 250.30M |
| March 06, 2024 | 253.68M |
| March 05, 2024 | 250.87M |
| March 04, 2024 | 251.43M |
| March 01, 2024 | 271.71M |
| February 29, 2024 | 256.61M |
| February 28, 2024 | 260.55M |
| February 27, 2024 | 246.50M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
87.60M
Minimum
Mar 23 2020
423.22M
Maximum
Nov 20 2019
223.23M
Average
204.25M
Median
Enterprise Value Benchmarks
| Zevra Therapeutics Inc | 191.81M |
| Madrigal Pharmaceuticals Inc | 3.817B |
| Viking Therapeutics Inc | 7.813B |
| Spero Therapeutics Inc | 14.10M |
| Karuna Therapeutics Inc (DELISTED) | 11.34B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.967M |
| Revenue (Quarterly) | 19.86M |
| Total Expenses (Quarterly) | 22.38M |
| EPS Diluted (Quarterly) | -0.09 |
| Gross Profit Margin (Quarterly) | 89.27% |
| Profit Margin (Quarterly) | -50.17% |
| Earnings Yield | -30.92% |
| Normalized Earnings Yield | -32.65 |